Results for mantle cell lymphoma translation from English to Estonian

mantle cell lymphoma
mantelrakuline lümfoom

mantle cell lymphoma (mcl)
mantelrakuline lümfoom (mrl)

mantle cell lymphoma and revlimid
mantelrakuline lümfoom ja revlimid

treatment of mantle cell lymphoma.
mantelrakulise lümfoomi ravi.

previously untreated mantle cell lymphoma
eelnevalt ravimata mantelrakuline lümfoom

mantle cell lymphoma (12 march 2013);
mantelrakuline lümfoom (12. märts 2013);

mantle cell lymphoma controlled phase ii study
mantelrakulise lümfoomi kontrolliga ii faasi uuring

mantle cell lymphoma single arm phase ii study
mantelrakulise lümfoomi ii faasi ühe rühmaga uuring

anaplastic large cell lymphoma.
anaplastiline suurrakklümfoom.

mantle cell lymphoma patients were not included in the pivotal study.
mantelrakulise lümfoomiga patsiente ravimuuringusse ei kaasatud.

dose adjustments during treatment for patients with previously untreated mantle cell lymphoma
annuste kohandamine ravi ajal eelnevalt ravimata mantelrakulise lümfoomiga patsientidel

for mantle cell lymphoma, multiple vials will be required for each dose over 25 mg.
mantelrakulise lümfoomi puhul on vaja iga rohkem kui 25 mg suuruse annuse manustamiseks mitut viaali.

previously treated mantle cell lymphoma, a type of cancer affecting the lymph nodes.
varem ravitud mantelrakuline lümfoom, mis on lümfisõlmi kahjustav vähk.

hepatosplenic t-cell lymphoma* (see 4.4)
hepatosplenaalne t-rakuline lümfoom* (vt 4.4)

cutaneous vasculitis anaphylaxis hepatosplenic t-cell lymphoma
hepatospleeniline t- rakklümfoom

for mantle cell lymphoma, velcade is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
mantelrakulise lümfoomi ravis kasutatakse velcadet kombineerituna rituksimabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.

table 3: adrs reported in clinical trials in patients with mantle cell lymphoma treated with lenalidomide
tabel 3: kõrvaltoimed, millest teatati kliinilistes uuringutes mantelrakulise lümfoomiga patsientidel, keda raviti lenalidomiidiga

for mantle cell lymphoma, bortezomib sun is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
mantelrakulise lümfoomi ravis kasutatakse bortezomib suni koos rituksimabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.

for mantle cell lymphoma, bortezomib accord is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
mantelrakulise lümfoomi ravis kasutatakse bortezomib accordi koos rituksimaabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.

torisel is not recommended in patients with mantle cell lymphoma who have moderate or severe problems with their liver.
toriseli ei soovitata kasutada nendel mantelrakulise lümfoomi patsientidel, kellel on maksaprobleeme.